ChemotherapyFDA-approvedFirst-line
Chemotherapy (e.g. Doxorubicin)
Generic name: doxorubicin
How it works
Interferes with DNA replication and cell division, causing cancer cells to die.
Cancer types
Breast Cancer— All patients
Efficacy
In clinical trials, patients with breast cancer who received chemotherapy had improved response rates and overall survival compared to those who received no treatment.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Biomarker for Heart Damage from Cancer Treatment | Breast Cancer | phase-2 | — | Source → |
| New Nanocarriers for Delivering Cancer Medicine | Breast Cancer | lab-study | The nanocarriers exhibited pronounced pH-dependent doxorubicin release and enhanced cytotoxicity toward MCF-7 cells (IC₅₀ = 0.8 ± 0.1 μM) | Source → |
| Evaluating Dapagliflozin to Prevent Heart Damage from Doxorubicin | Breast Cancer | phase-2 | — | Source → |
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Microneedle Patch Improves Doxorubicin Delivery for Breast Cancer | Breast Cancer | animal-study | Tumor inhibition rate was 90.61% in a 4T1 tumor-bearing mouse model. | Source → |
| Doxorubicin Resistance Found in Leukemia Cells Grown in Lab | Leukemia | lab-study | Only 0.26±0.21% of the resistant cells entered late apoptosis after 24h doxorubicin exposure. | Source → |
| Understanding Resistance to Doxorubicin in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Nanoparticle Delivery System Shows Promise for Lung Cancer Treatment | Lung Cancer | lab-study | The IC50 value was 1.36 μM, compared to 1.9 μM for free DOX. | Source → |
| Pegylated Liposomal Doxorubicin and Immunotherapy in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Detecting Cancer Drug Concentration in Cells | Breast Cancer | lab-study | — | Source → |
| Overcoming Doxorubicin Resistance in Ovarian Cancer Cells | Ovarian Cancer | lab-study | Substantial resensitization of A2780ADR cells to Doxo was achieved by verapamil (Ver). | Source → |
| Doxorubicin Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Combining Doxorubicin and Zm-093 May Enhance Apoptosis in Breast Cancer Cells | Breast Cancer | lab-study | The combined treatment resulted in a 57% reduction in Bcl-2 expression compared to the control group. | Source → |
| Combining drugs may help fight aggressive breast cancer | Breast Cancer | lab-study | Treatment with SB431542 and doxorubicin used in combination significantly reduced cell viability (CDI 0.54-0.63) | Source → |
| New Delivery System for Colorectal Cancer Treatment | Colorectal Cancer | lab-study | The tumor suppression rate reached 42.55 ± 0.18%. | Source → |
| Long non-coding RNA STMN1P2 linked to breast cancer resistance to doxorubicin | Breast Cancer | lab-study | — | Source → |
| New Compound Shows Promise in Treating Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Dichloroacetate Enhances Chemotherapy Effectiveness in Some Breast Cancer Cells | Breast Cancer | lab-study | The cell line MCF7 exhibited the highest rate of inhibition, followed by MDA-MB-231 and T47D. | Source → |
| Doxorubicin's kidney damage linked to SIRT1/HSF1 pathway | Ovarian Cancer | animal-study | — | Source → |
| Ovarian Cancer and Heart Damage: New Research and Treatment Strategies | Ovarian Cancer | review | — | Source → |
| Combining Cold Plasma and Doxorubicin May Help Fight Melanoma | Melanoma | meta-analysis | The pooled analysis found that the CAP and DOX combination had a significant effect on cell viability (ES = 6.75, 95% CI 1.65 to 11.85) and cytotoxicity (ES = 11.71, 95% CI 3.69 to 19.73). | Source → |
| Viscosity Affects Colon Cancer Cells' Resistance to Doxorubicin | Colorectal Cancer | lab-study | — | Source → |
| New Tool Helps Target Cancer Treatment with Light | Ovarian Cancer | lab-study | — | Source → |
| Pegylated Liposomal Doxorubicin Shows Promise in Ovarian Cancer Treatment | Ovarian Cancer | phase-2 | The median progression-free survival was 6.8 months (95% CI, 4.4-9.3 months), and the median overall survival was 19.1 months (95% CI, 15.0-23.3 months). | Source → |
| Understanding Chemotherapy Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Hydrogel System Tested for Treating Melanoma | Melanoma | lab-study | — | Source → |
| Understanding Doxorubicin's Effectiveness in Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Nanoparticles Deliver Cancer Drugs More Effectively | Breast Cancer | lab-study | BBR/CS-DOX demonstrated stronger pro-apoptotic and anti-metastatic effect in vitro and in vivo, respectively | Source → |
| Doxorubicin Resistance Linked to Gene Expression Changes | Colorectal Cancer | lab-study | — | Source → |
| Researchers Investigate Doxorubicin Resistance in Leukemia Cells | Leukemia | lab-study | — | Source → |
| Propofol May Enhance Effectiveness of Ovarian Cancer Treatments | Ovarian Cancer | lab-study | — | Source → |
| Cancer Gene Linked to Doxorubicin Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | The tumor growth inhibition rate rose in the si-CASC11 group in comparison with that in the si-NC group (P < 0.05). | Source → |
| Cancer Cells May Develop Resistance to Doxorubicin with Help from Surrounding Tissue Cells | Ovarian Cancer | lab-study | — | Source → |
| Cadmium-based Complex Loaded with Doxorubicin Shows Promise Against Leukemia | Leukemia | lab-study | — | Source → |
| Targeted Cancer Treatment Shows Promise for Colorectal Cancer | Colorectal Cancer | lab-study | DOX-P exhibited superior antitumor activity against colorectal cancer than that of DOX. | Source → |
| STK32C and Doxorubicin Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Targeted Cancer Therapy Using Smart Nanosystem | Breast Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells Show Resistance to Platinum-Based Chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| Trabectedin's Role in Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| New Compound Enhances Effectiveness of Cancer Treatment in Lab Experiments | Breast Cancer | lab-study | — | Source → |
| Hypertension and Heart Failure in Breast Cancer Patients | Breast Cancer | observational | The RAS inhibitor group had a lower risk for primary outcome (adjusted HR = 0.78, 95% CI = 0.65-0.94) and death (adjusted HR = 0.81, 95% CI = 0.66-0.99) compared to the non-HT group. | Source → |
| Targeting Prion Protein to Overcome Chemotherapy Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.